The company said that the new purification facility will expand its capacity to produce active pharmaceutical ingredients (APIs) for a growing number of diabetes drugs under development.
The new facility, which will have a total area of 2,700m², is expected to be fully operational by late 2016 and will be operated by CMC Supply (Chemistry, Manufacturing and Control Supply), a unit within Novo Nordisk R&D.
CMC Supply is focused in the development, production and formulation of all new protein and peptide processes in Novo Nordisk.
CMC Supply senior vice president Jesper Bøving said the new purification pilot plant will significantly increase company’s capacity for early-phase diabetes projects.
"It will create up to 35 new jobs over a two-year period in addition to the 100 new employees CMC Supply will hire in Denmark in 2014," Bøving added.
Initially, the project includes establishment of a pilot plant with one purification line and later the facility can be expanded to the double size to further increase the capacity.
Image: Novo Nordisk’s new $100m plant designed to produce diabetes drugs will be fully operational by late 2016. Photo: courtesy of Novo Nordisk